Novo Nordisk's Credibility Gap: The Market Wants More Than Better Numbers
Published on 08/14/2026 at 09:51 | Redaktion boerse-global.de
There comes a point in every industry narrative when the numbers stop mattering. Novo Nordisk appears to have reached it. The Danish drugmaker delivered a second-quarter performance that most companies would celebrate — adjusted sales up 7 percent on a currency-adjusted basis, operating profit ahead 11 percent — and then watched its shares fall more than 4 percent the following day while rival Eli Lilly climbed over 7 percent.
The market's message was unmistakable: beating your own lowered expectations is no longer enough when the competitive ground is shifting beneath you.
A Guidance Upgrade That Failed to Convince
The company's revised outlook for 2026 was genuinely better. Where Novo Nordisk had previously warned of a sales decline of up to 12 percent, it now projects either stable development or a contraction of no more than 6 percent. Yet investors shrugged. The stock now trades at €39.91, down 1.4 percent on the day and 9.5 percent lower over the past month. From its January peak of €54.86, the shares have retreated 27 percent, though they still sit 32 percent above the early-March low.
The pattern is telling. Novo Nordisk is no longer being judged on its own merits but on its standing relative to Eli Lilly in the race for supremacy in the weight-loss market. Delivering merely "better than feared" while the competitor gains ground invites punishment, even with an upgraded forecast attached.
Management's Response: Speed Over Consolation
Chief executive Mike Doustdar has recognized that financial cosmetics won't suffice. He has pledged to accelerate research efforts and explore complementary acquisitions — an acknowledgment that the future narrative, not the current quarter's figures, now dictates the share price. In a market that has transformed within a few short years from a duopoly into a genuine arms race, pipeline strength matters more than quarterly results.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The pressure comes from multiple directions. A Dutch court issued an injunction in a patent dispute involving the semaglutide product Ceban. At Scholar Rock Holdings, a Novo Nordisk manufacturing facility was removed from a regulatory filing for a muscle-wasting drug following a warning from the US Food and Drug Administration. Individually, these are minor setbacks. Collectively, they paint a picture of a company fighting on several fronts while its chief rival advances with apparent ease.
The CagriSema Question
The central test for the investment case is whether CagriSema can defend market share against Eli Lilly's next-generation offering. The phase 3b REDEFINE 9 study completed recently, showing placebo-adjusted weight loss with lower maintenance doses that was superior to the comparator, with a safety profile consistent with earlier trials. The clinical substance appears solid — the open questions are timing and pricing.
Doustdar has argued that the obesity market will accommodate multiple winners rather than a single duel, pointing to Novo Nordisk's control of 90 percent of the oral GLP-1 segment as a buffer while CagriSema finds its footing. Eli Lilly, meanwhile, confirmed on August 7 its timeline for FDA submission of its next-generation product, intensifying pressure on the Wegovy franchise.
Diverging Analyst Views
The analyst community reflects the broader uncertainty. On August 7, Citi cut its price target to 310 Danish kroner from 330, while Landesbank Baden-Württemberg trimmed its target to 320 from 330 kroner — both maintaining neutral-to-cautious stances. SB1 Markets moved in the opposite direction, raising its target to 370 from 360 kroner with a buy recommendation.
Berenberg has since downgraded the stock from "Buy" to "Hold," reducing its price target from $50 to $47, citing Eli Lilly's growing dominance and concerns about the CagriSema launch. The shares closed Thursday at €40.45, just below their 50-day average of €41.29.
Operational Strength Persists
Despite the market's skepticism, the company continues to operate with conviction. Since the guidance announcement in early August, Novo Nordisk repurchased 13.125 million B-shares for approximately 3.98 billion Danish kroner through August 7, part of a program running until February 2027 with a volume of up to 11.2 billion kroner. This is not the behavior of a management in panic but of one confident in its cash flows and willing to invest in its own equity while others doubt.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The second-quarter numbers support that confidence. Adjusted revenue reached 78.5 billion Danish kroner, with adjusted operating profit of 33.4 billion kroner — comfortably ahead of analyst estimates of 28.74 billion kroner. The Wegovy pill has surpassed 5 million prescriptions in the US since launch, with more than 265,000 weekly scripts in mid-July.
The Risks Beneath the Surface
Not everything in the pipeline is delivering. The phase 3 ZEUS study of Ziltivekimab, examining cardiovascular endpoints, missed its primary goal and triggered a non-cash impairment charge of 6.3 billion kroner on pipeline assets. The 90 percent oral-segment dominance offers protection only as long as patients and physicians don't migrate en masse to injectable alternatives from competitors.
The stock's 39 percent volatility over 30 days and an RSI of 44.8 suggest the market itself remains undecided. The next concrete test comes with the EU launch of the Wegovy 7.2 mg single-dose pen in the second half of the year, following EMA approval in July, and the expanded partnership with Amazon Web Services to accelerate early drug discovery signals a broader innovation strategy beyond CagriSema alone.
The real question for the months ahead is not whether Novo Nordisk can deliver — it has demonstrated that it can. It is whether the pace of research and potential acquisitions will be enough to restore the company's position as the pace-setter in the weight-loss market in investors' minds, rather than a pursuer.
Ad
Novo Nordisk Stock: New Analysis - 14 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
